Overview

Healthcare professionals typically want to know whether patients with severe alopecia areata will respond to treatment, how long this will take, and how much hair regrowth is possible. Prof. Vañó discusses distinct patterns of response to Olumiant observed in clinical trials and real-world clinical experience, and how these may help guide clinical decision-making and inform patient expectations.

This Class for

Physician

What I will learn?

What will I learn?

Understand how response patterns to Olumiant may shape treatment decisions and follow-up discussions for patients with severe AA

Disclaimer:

CMAT-39379 | Privacy Policy | PI Information for Olumiant®

This information is intended for Health Care Professionals only.

This content is approved by Eli Lilly and company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission.

If you have any comments on the provided materials please communicate
such to the SFDA on the unified number: 19999

For adverse events and safety reporting:
email: [email protected]
24 /7 mobile: +966 567 868 843
Working hours Tel: +966 11 461 7800 , Ext: 1

For any product complaints (PCs), suspected counterfeits, or tampering
with Lilly products, please report them via email at
[email protected] 24/7, mobile: +966 567 868 843 working
hours: +966 11 461 7800, Ext: 1

For Lilly product information:
email: [email protected]

For further information, please contact:
Eli Lilly and Company, Scientific Office
P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia.
Tel: +966 11 461 7800
Fax: +966 111 217 9900